- en: <!--yml
  id: totrans-split-0
  prefs: []
  type: TYPE_NORMAL
- en: 'category: 未分类'
  id: totrans-split-1
  prefs: []
  type: TYPE_NORMAL
- en: 'date: 2024-05-27 14:30:37'
  id: totrans-split-2
  prefs: []
  type: TYPE_NORMAL
- en: -->
  id: totrans-split-3
  prefs: []
  type: TYPE_NORMAL
- en: 'cancer treatment: Tata Institute claims only Rs 100 tablet can prevent recurrence
    of cancer - The Economic Times'
  id: totrans-split-4
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
- en: 来源：[https://economictimes.indiatimes.com/news/science/tata-institute-claims-new-breakthrough-cancer-treatment-only-costs-rs-100-heres-what-they-said/articleshow/108058030.cms?from=mdr](https://economictimes.indiatimes.com/news/science/tata-institute-claims-new-breakthrough-cancer-treatment-only-costs-rs-100-heres-what-they-said/articleshow/108058030.cms?from=mdr)
  id: totrans-split-5
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
- en: The
  id: totrans-split-6
  prefs: []
  type: TYPE_NORMAL
- en: '[Tata Institute](/topic/tata-institute)'
  id: totrans-split-7
  prefs: []
  type: TYPE_NORMAL
- en: in Mumbai has announced a groundbreaking discovery in
  id: totrans-split-8
  prefs: []
  type: TYPE_NORMAL
- en: '[cancer treatment](/topic/cancer-treatment)'
  id: totrans-split-9
  prefs: []
  type: TYPE_NORMAL
- en: . After a decade of research, they have developed a tablet that could prevent
    cancer from recurring and reduce the
  id: totrans-split-10
  prefs: []
  type: TYPE_NORMAL
- en: '[side effects](/topic/side-effects)'
  id: totrans-split-11
  prefs: []
  type: TYPE_NORMAL
- en: of treatment by 50%.
  id: totrans-split-12
  prefs: []
  type: TYPE_NORMAL
- en: Breakthrough Discovery
  id: totrans-split-13
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
- en: Researchers and doctors at the Tata Institute have developed a tablet that they
    claim can prevent the recurrence of cancer and reduce side effects of treatments
    like radiation and chemotherapy by 50%. The tablet, named 'R+Cu', contains pro-oxidant
    tablets with
  id: totrans-split-14
  prefs: []
  type: TYPE_NORMAL
- en: '[resveratrol](/topic/resveratrol)'
  id: totrans-split-15
  prefs: []
  type: TYPE_NORMAL
- en: and
  id: totrans-split-16
  prefs: []
  type: TYPE_NORMAL
- en: '[copper](/topic/copper)'
  id: totrans-split-17
  prefs: []
  type: TYPE_NORMAL
- en: ', which generate oxygen radicals in the stomach. These radicals destroy chromatin
    particles released by dying cancer cells, preventing them from turning healthy
    cells cancerous. This process also inhibits the movement of cancer cells from
    one part of the body to another, known as '''
  id: totrans-split-18
  prefs: []
  type: TYPE_NORMAL
- en: '[Metastases](/topic/metastases)'
  id: totrans-split-19
  prefs: []
  type: TYPE_NORMAL
- en: '''.'
  id: totrans-split-20
  prefs: []
  type: TYPE_NORMAL
- en: '**Testing and Approval**'
  id: totrans-split-21
  prefs: []
  type: TYPE_NORMAL
- en: Dr. Rajendra Badve, a senior cancer surgeon at
  id: totrans-split-22
  prefs: []
  type: TYPE_NORMAL
- en: '[Tata Memorial Hospital](/topic/tata-memorial-hospital)'
  id: totrans-split-23
  prefs: []
  type: TYPE_NORMAL
- en: ', stated that the tablet has been tested on rats for its effect on side effects
    and prevention, with promising results. However, human trials are yet to be completed,
    which could take about five years. The tablet is awaiting approval from the Food
    Safety and Standards Authority of India (FSSAI) and is expected to be available
    in the market by June-July.'
  id: totrans-split-24
  prefs: []
  type: TYPE_NORMAL
- en: '**Affordable Treatment**'
  id: totrans-split-25
  prefs: []
  type: TYPE_NORMAL
- en: One of the most significant aspects of this breakthrough is its affordability.
    While cancer treatment can cost lakhs to crores, this tablet is expected to be
    available for just ₹100, making it accessible to a larger population.
  id: totrans-split-26
  prefs: []
  type: TYPE_NORMAL
- en: '"Tata doctors were working on this tablet for almost a decade. The tablet is
    awaiting approval from the Food Safety and Standards Authority of India (FSSAI).
    TIFR scientists have applied to FSSAI to approve this tablet. After getting the
    approval, it will be available in the market from June-July. This tablet will
    help to a great extent in improving cancer treatment," the senior cancer surgeon
    said in an interview with'
  id: totrans-split-27
  prefs: []
  type: TYPE_NORMAL
- en: '[NDTV](/new-delhi-television-ltd/stocks/companyid-16783.cms)'
  id: totrans-split-28
  prefs: []
  type: TYPE_NORMAL
- en: .
  id: totrans-split-29
  prefs: []
  type: TYPE_NORMAL
- en: '"While the budget for the treatment ranges from lakhs to crores, this tablet
    will be available everywhere for just ₹ 100," he said.'
  id: totrans-split-30
  prefs: []
  type: TYPE_NORMAL
- en: '**Future Prospects**'
  id: totrans-split-31
  prefs: []
  type: TYPE_NORMAL
- en: The tablet not only shows promise in preventing the recurrence of cancer but
    also in reducing side effects of treatment. The researchers believe it could be
    effective in treating pancreatic, lung, and oral cancers.
  id: totrans-split-32
  prefs: []
  type: TYPE_NORMAL
- en: The development of this tablet marks a significant breakthrough in cancer treatment,
    offering hope to patients and potentially revolutionizing the way cancer is treated.
    Its affordability and effectiveness could make it a game-changer in the field
    of oncology.
  id: totrans-split-33
  prefs: []
  type: TYPE_NORMAL
